rs10192566

A SNP in the LPIN1 gene on chromosome 2. Its most notable genotype is C;C: if diabetic, poorer response to rosiglitazone

Gene
LPIN1
Location
Chr 211,750,302 (GRCh38)
Highest magnitude
0.0Typical
Tested on
23andMe
Minor allele frequency
47%

Genotypes

As shown in 23andMe and AncestryDNA files.

  1. C;CMost notableNot ratedif diabetic, poorer response to rosiglitazoneTypical · 0.0
  2. C;GNot ratedif diabetic, better response to rosiglitazoneTypical · 0.0
  3. G;GNot ratedif diabetic, better response to rosiglitazoneTypical · 0.0

On SNPedia: (C;C), (C;G), (G;G). Magnitude rates how notable a genotype is from 0 to 10, not how risky it is.

Conditions, medicines and genes

Other LPIN1 SNPs

All LPIN1 SNPs

Notes

From SNPedia

Notes

A total of 262 Korean type-2 diabetes patients were treated with 12 weeks of rosiglitazone at 4mg/day and genotyped to reveal that rs10192566(G) allele carriers responded better than (C) carriers. Patients with rs10192566(G) alleles had a larger decrease in fasting plasma glucose, 2-h postprandial glucose, and HbA1c than rs10192566(C;C) homozygotes. None of the other LPIN1 gene SNPs tested were associated with response. Note: rs11693809, rs10192566, and rs2278513 are in nearly complete linkage disequilibrium (D'>0.958, r(2) >0.882).

Source and license

Adapted from rs10192566 on SNPedia, using a snapshot taken October 16, 2026. SNPedia content is shared under CC BY-NC-SA 3.0 US, and this page is shared under the same license.

SNPedia is a community-edited wiki. Its entries can be incomplete, out of date or wrong, and nothing here is a diagnosis or medical advice. Magnitude is a community rating of how interesting a genotype is, not a risk score.